推荐产品
等级
certified reference material
质量水平
形式
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol (as free base)
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
格式
single component solution
储存温度
−20°C
SMILES字符串
Cl.CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c3ccccc13
InChI
1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1
InChI key
BLFQGGGGFNSJKA-XHXSRVRCSA-N
基因信息
human ... SLC6A4(6532)
一般描述
Sertraline, marketed as the brand drug Zoloft®, is an SSRI antidepressant used in the treatment of major depression as well as obsessive-compulsive, panic, and social anxiety disorders. This Certified Snap-N-Spike® Solution is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.
应用
- Environmental impact assessment: Sertraline hydrochloride is analyzed for its environmental effects, particularly focusing on its metabolites and their reactive properties. This research is critical for assessing the potential ecological risks associated with pharmaceuticals (Jin et al., 2024).
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zoloft is a registered trademark of Pfizer, Inc.
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 1 - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
WGK
WGK 3
闪点(°F)
closed cup
闪点(°C)
closed cup
法规信息
危险化学品
Andre R Brunoni et al.
JAMA psychiatry, 70(4), 383-391 (2013-02-08)
Transcranial direct current stimulation (tDCS) trials for major depressive disorder (MDD) have shown positive but mixed results. To assess the combined safety and efficacy of tDCS vs a common pharmacological treatment (sertraline hydrochloride, 50 mg/d). Double-blind, controlled trial. Participants were
Quang A Le et al.
Health and quality of life outcomes, 11, 59-59 (2013-04-17)
To determine the minimal clinically important difference (MCID) for the health-utility measures EuroQol-5 dimensions (EQ-5D) and Quality of Well Being Self-Administered (QWB-SA) Scale in PTSD patients. Two hundred patients aged 18 to 65 years with PTSD enrolled in a doubly
Latif Moradveisi et al.
The British journal of psychiatry : the journal of mental science, 202(3), 204-211 (2013-02-09)
Behavioural activation might be a viable alternative to antidepressant medication for major depressive disorder. To compare the effectiveness of behavioural activation and treatment as usual (TAU, antidepressant medication) for major depressive disorder in routine clinical practice in Iran. Patients with
Alastair J Flint et al.
BMC psychiatry, 13, 38-38 (2013-01-29)
Psychotic depression (PD) is a severe disabling disorder with considerable morbidity and mortality. Electroconvulsive therapy and pharmacotherapy are each efficacious in the treatment of PD. Expert guidelines recommend the combination of antidepressant and antipsychotic medications in the acute pharmacologic treatment
R Kaddurah-Daouk et al.
Translational psychiatry, 3, e223-e223 (2013-01-24)
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline or placebo in a double-blind 4-week
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门